A preliminary study of NER and MMR pathways involved in chemotherapy response in bladder transitional cell carcinoma: Impact on progression-free survival by Montazeri, V. et al.





A Preliminary Study of NER and MMR Pathways Involved 
in Chemotherapy Response in Bladder Transitional Cell 
Carcinoma: Impact on progression-free survival
Vahideh Montazeria, Mohammad Hossein Ghahremania, Hamed Montazerib,  
Mandana Hasanzadc, d, Majid Safavie, Mohsen Ayatif, Mohammad Chehrazig,  
Baharak Arefi Moghaddamh and Seyed Nasser Ostadi*
aDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University 
of Medical Sciences, Tehran, Iran. bDepartment of Pharmaceutical Biotechnology, School of 
Pharmacy, International Campus, Iran University of Medical Sciences, Tehran, Iran. cMedical 
Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 
dPersonalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences 
Institute, Tehran University of Medical Sciences, Tehran, Iran. eUrology Research Center, Tehran 
University of Medical Sciences, Tehran, Iran. fUro-Oncology Research Center, Tehran University 
of Medical Sciences, Tehran, Iran. gDepartment of Biostatistics and Epidemiology, School of 
Public Health, Babol University of Medical Sciences, Babol, Iran. hImam Khomeini Hospital, 
Tehran University of Medical Sciences, Tehran, Iran. iToxicology and Poisoning Research 
Centre, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University 
of Medical Sciences, Tehran, Iran.
* Corresponding author: 
    E-mail: ostadnas@tums.ac.ir
Abstract
One of the main genotoxic drugs used in bladder cancer chemotherapy is cisplatin. While it is 
applied in most types of cancers, resistance to cisplatin is wildly common. In order to overcome 
drug resistance, it is necessary to determine a predictive marker. This study was conducted to 
provide basic data for selecting and designing a gene profile for further cohort and RCT studies in 
the future to improve response to treatment in bladder cancer. The expression levels of ERCC1, 
MLH1, MSH2, and CTR1 mRNA were determined in the tumor tissue using real-time q-PCR. 
Progression-free survival (PFS) was analyzed in term of the level of genes expression. The results 
revealed that the level of ERCC1 mRNA expression was higher in the recurrence (R) group 
compared to the no recurrence (NR) group. Moreover, the PFS time was increased in the patients 
with an ERCC1 expression level of below 1.57. The level of MLH1 and MSH2 mRNA expression 
was lower in the R group compared to the NR group; therefore, PFS time was increased in the 
patients with MLH1 and MSH2 gene expression levels above the cutoff point. While the level 
of CTR1 mRNA expression was higher in the R group versus the NR group, the PFS time was 
longer in the patients with CTR1 expression levels of below 1.265 compared to the patients with 
high levels of CTR1 expression. It can be concluded that the level of ERCC1, MLH1, MSH2, 
and CTR1 mRNA expression may be associated with PFS time as possible therapeutic targets for 
decreasing cisplatin resistance.  
Keywords: Carcinoma; Transitional cell; Progression-free survival; Copper transporter 1 
protein; Human; Cisplatin.
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Introduction
Bladder cancer (BC) is the ninth most 
prevalent cancer with a global incidence 
of about 430,000 new cases every year. 
According to epidemiological studies, the 
highest prevalence of BC is seen in North 
America, Europe, and Western Asia (1, 2). 
The incidence ratio of BC in men is 3.3 
time as high as in women. It is reported as the 
13th cause of mortality worldwide by cancer 
per year and tobacco smoking is known as 
the main risk factor (1). The Tumor- Node- 
Metastasis system (TNM system) is used for 
staging tumors, which explains tumor invasion 
(Tis- T4). Tumor grading is based on the cellular 
characteristics (3). Based on histological 
characteristics, transitional cell carcinoma 
(TCC) is the most common type of BC (˃90%), 
which originates from the uroepithelium (4, 
5). There are two types of TCC with different 
clinical symptoms. The majority of the TCC 
cases (≥70%) are categorized into low-grade 
non-muscle invasive bladder cancer (NMIBC) 
subtype. NMIBC is restricted to the mucosa 
or submucosa and is treated locally using 
transurethral resection (TUR) (1, 6 and 7). 
Muscle-invasive bladder cancer (MIBC) is 
another subtype of TCC that includes 20-25% 
of cases and is life-threating due to metastasis 
and invasion to distant sites. Clinical studies 
reported that about 50% of the patients with 
this type of cancer have a poorer 5-year 
survival and lower quality of life (6, 7).
The recurrence and metastasis mechanism 
of the tumor is not clear. Therefore, knowledge 
of the molecular mechanisms seems to be 
necessary for early diagnosis and treatment 
decisions (8). Radical cystectomy and 
chemotherapy using cisplatin is the standard 
treatment for MIBC. However, the treatment 
strategy depends mostly on the clinico- 
pathologic pattern as well as staging (7, 9). 
Cisplatin [cisdiamminedichloroplatinum 
(II)], a genotoxic drug, is a platinum- based 
drug that binds to DNA and alters its structure. 
In fact, steric fluctuation in the helix by 
cisplatin causes higher propensity to the 
interstrand DNA cross-link. These lesions 
in the intracellular DNA structure inhibit 
replication and transcription of DNA, which in 
turn triggers apoptosis in cells (10-13). Many 
mechanisms contribute to drug resistance, 
especially resistance to cisplatin. DNA damage 
response (DDR) pathways play a critical role 
in response to chemotherapy. DDR pathways 
include many proteins, especially the 
nucleotide excision repair (NER) system that 
affects drug resistance through recognizing and 
removing DNA lesions produced by cisplatin 
(14, 15). In this system, Excision Repair 
Cross Complementing 1 (ERCC1) is the main 
protein and a critical factor in recognizing and 
removing cisplatin adducts (15, 16). 
Mismatch Repair Pathway (MMR) is 
another component of the DDR pathway 
involved in drug resistance. Mut L Homologue 
1 (MLH1) and Mut S Homologue 2 (MSH2) 
have a critical role in the normal function 
of the MMR pathway (11, 17). Defects in 
the MMR pathway are related to cisplatin 
resistance, and decreased expression levels of 
MLH1 mRNA lead to cisplatin resistance in 
different cancers (18, 19). The effect of MSH2 
in cisplatin resistance is also revealed in other 
studies (11, 20). Cisplatin is the backbone of 
bladder cancer treatment regimens and causes 
DNA damage through alkylation; therefore, 
faulty NER and MMR genes as components 
of the DNA repair pathways can cause drug 
resistance and tumor progression (17, 21-23).
It should also be noted that the mechanism of 
cisplatin resistance is multifactorial, including 
decreased intratumoral cisplatin accumulation 
due to diminished activity of transporters. 
Copper Transporter 1 (CTR1; SCLC31A1, 
or hCTR1) is the main transporter on the cell 
membrane contributing to cooper hemostasis 
with a crucial role in cisplatin uptake in tumor 
cells. Many studies have indicated that the 
level of CTR1 mRNA expression could have 
an impact on cisplatin resistance (10, 24-26). 
This study was conducted to evaluate 
association between MLH1, MSH2, ERCC1, 
and CTR1 expression in bladder tumor tissues 
and cisplatin resistance in Iranian BC patients.
Experimental
 Patients and sample collection
The study was done in the Urology 
Research Center of Sina Hospital and Uro-
Oncology Research Center of Imam Khomeini 
Hospital affiliated of Tehran University of 
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Medical Sciences (TUMS). It was designed 
according to the Declaration of Helsinki and 
approved by the Ethics Committee of TUMS 
(IR.TUMS.REC.1395.2389). The participants 
were recruited prospectively from April 
2016 to November 2018 according to the 
clinicopathological diagnosis. The inclusion 
criteria were a histopathological report of 
TCC, tumor grades T2 and T3 (N0, M0), 
age ≤80 years old, and a negative history of 
treatment with radiotherapy or chemotherapy 
and immunotherapy. Patients who had 
metastatic cancer from other sites or underwent 
chemotherapy or radiotherapy were excluded 
from the study. Informed consent was taken 
from all participants. Fresh tumor tissues were 
obtained from the patients during transurethral 
resection (TUR) or radical cystectomy, 
maintained in RNA latter (Que Gene), and 
stored at -20 °C for RNA extraction. 
Clinical data
Demographic data such as age, smoking, 
BMI, and pathological data including tumor 
grading and staging were recorded. All patients 
received cisplatin- based chemotherapy regi-
mens and response to chemotherapy was 
assessed four weeks after chemotherapy 
finished (27). All clinical documents of 
patients such as physical examination, imaging 
studies including chest X-ray and abdominal 
and pelvic CT scans were assessed. Response 
to chemotherapy was evaluated based on the 
criteria for solid tumor progression including 
recognizable tumors in other sites or in the 
same tissue diagnosed by cystoscopy and 
imaging. 
RNA extraction and gene expression 
analysis using Real Time PCR 
The expression levels of ERCC1, MLH1, 
MSH2, and CTR1 were determined using 
real-time quantitative reverse transcriptase- 
polymerase chain reaction (real-time RT-
PCR). The RNA content was isolated from 
the tumor tissues maintained in RNA latter 
(QiaGen) using Trizol reagent and stored 
at -70 °C. The information about the RNA 
yield was estimated using spectrophotometer 
absorbance (Eppendorf 6131, Bio Photometer) 
and the ratio of 260/250 nm was calculated. 
Complementary DNA (cDNA) synthesis 
was performed using a cDNA synthesis kit 
(Takara, Otsu, Shiga, Japan) according to 
the manufacturer’s instructions and stored 
at -70 °C. The primers are listed in Table 1. 
Furthermore, TBP (TATA box binding protein) 
and SDHA (succinate dehydrogenase complex, 
subunit A, flavoprotein) were determined as 
internal reference genes (28). The level of 
mRNA expression was determined with the 
Applied Biosystems StepOnePlus Real-time 
PCR using SYBR Premix Ex Taq™ II (Tli 
RNaseH Plus; Takara) in a 10-µL final volume. 




































Table 1. List of primer.
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Data were analyzed according to the 
quantitative assessment of the change in the 
expression value of each gene relative to 
the housekeeping gene using 2-(ΔCt sample- ΔCt 
housekeeping). Furthermore, the expression levels 
of these genes were evaluated in tumors and 
adjacent normal samples relative to the SDHA 
housekeeping gene.
Statistical Analysis
The data are presented using mean (SD), 
frequency, and 95% confidence interval (95% 
CI). Independent sample t-test or Mann– 
Whitney U test and chi-square test were used 
to investigate the differences in continuous 
and categorical variables, respectively. The 
Kaplan-Meier method was applied to depict 
univariate survival curves illustrating the 
association between the biomarker expression 
and Progression-Free Survival (PFS). PFS 
was defined from four weeks after the end of 
chemotherapy until the time of recurrence. 
The log- rank test was applied to assess the 
statistical significance between survival 
curves. The Cox proportional hazard model 
was used to estimate the hazard ratio of 
recurrence for the gene expression. The cutoff 
point was calculated according to receiver 
operating characteristic (ROC) curve and 
Youden index. The ROC curve plotted the 
sensitivity (true positives) against 1- specificity 
(false positives), considering each value as a 
possible cutoff value. p-values less than 0.05 
(p-value ≤ 0.05) were considered significant 
in all analyses. All statistical analyses were 
performed using the STATA version 15 
(STATA Corp, College Station, Texas).
Results
Patients
Of 25 eligible patients, 12 finished the 
study successfully (Figure 1). During the 
follow-up period, 5 patients showed recurrence 
on cystoscopy and were referred for radical 
cystectomy. There was no significant differ-
ence in average age between the two groups 
(63 years in NR group and 62 years in R 
group). There was no significant difference 
in the smoking profile between the two 
groups while opium consumption was more 
common in the R group versus the NR group. 
Demographic results showed no statistically 
significant difference in age, smoking, opium 
consumption, and BMI between the two 
groups. Baseline characteristics of patients 
are summarized in Table 2. In the NR group, 
25% and 75% tumor tissues were classified as 
T2b and T3, respectively. By contrast, in the 
R group, 75% and 25% of the tumors were 
classified as T2b and T3, respectively. There 
was no significant difference in the tumor 
grade and TMN (tumor, metastasis, node) 
staging between the two groups (p-value ≥ 
0.05). 
Assessment of gene expression in patients 
The expression levels of ERCC1, MLH1, 
MSH2, and CTR1 mRNA were evaluated using 
SYBER GREEN Real Time- PCR method. As 
indicated in Figure 2, the expression levels of 
MLH1 and MSH2 were lower in the R group 
compared to the NR group. By contrast, the 
expression levels of ERCC1 and CTR1 were 
higher in the R group versus the NR group. No 
significant relationship was observed between 
the mRNA expression of MLH1, MSH2, 
ERCC1, and CTR1 in two groups (p-value ≥ 
0.05). 
Level of gene expression and response to 
chemotherapy
Response to chemotherapy was 58.33% in 
12 patients in this study. The risk of disease 
recurrence was calculated using the expression 
levels of MLH1, ERCC1, MSH2, and CTR1 
mRNA below and above the cutoff point. The 
risk of disease recurrence was higher when 
the expression levels of MLH1 and MSH2 
mRNA were below the cutoff points (57.1 
and 20%; p = 0.19, respectively). There was 
no correlation between the expression level 
of MLH1 and MSH2 mRNA and response to 
chemotherapy in the R group. Furthermore, 
the risk of disease recurrence increased when 
the expression levels of ERCC1 mRNA were 
above the cutoff point. In this group, the risk of 
disease recurrence when the expression levels 
of ERCC1 and CTR1 mRNA expression were 
above the cutoff point was 60% (p = 0.27) and 
57.1% (p = 0.19), respectively. There was no 
significant correlation between the value of 
gene expression and tumor recurrence in the R 
group (Table 3). The survival of the patients in 
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Figure 1. Patient's papulation. Figure 1. Patient’s papulation.
Table 2. Demographic and clinicopathological characteristic of patients.  
Characteristics NR (n = 7) 
R 
(n = 5) p-value 
Age 63 ± 10.94 62.40 ± 5.68 0.64 

















































NR: No recurrence group; R: Recurrence group. 
  
Table 2. Demographic and clinicopathological characteristic of patients. 
the NR group was higher when the expression 
levels of MLH1 and MSH2 mRNA were 
below the cutoff point. The survival was also 
increased in the NR group when the expression 
levels of ERCC1 and CTR1 mRNA were 
above the cutoff point (Table 3). No significant 
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correlation was observed between ERCC1 and 
CTR1 mRNA expression levels and outcome 
of BC in the NR group.
Relationship between levels of genes 
expression and survival of patients
As shown in Table 4, the median survival 
was calculated for each gene above and below 
the cutoff point values. Based on the results, 
patients with expression levels of MLH1 and 
MSH2 below the cutoff point had a median 
survival of 17 months (95% CI = 0-45.22) and 
6 months (95% CI = 4.17-7.28), respectively. 
It was clearly demonstrated that the patients 
with MLH1 mRNA expression level below the 
cutoff point were high risk patients compared 
 
 
Figure 2. Expression levels of MLH1, ERCC1, MSH2, and CTR1 in NR and R groups (mean ± SD). 
Figure 2. Expression levels of MLH1, ERCC1, MSH2, and CTR1 in NR and R groups (mean ± SD).
Table 3. Assessment of relationship between risk of recurrence and gene expression levels below and above the cutoff point. 
Gene 
Cutoff point 

















































NR: no recurrence group; R: recurrence group. 
  
Table 3. Assessment of relationship between risk of recurrence and 
gene expression levels below and above the cutoff point.
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Table 4. Assessment of relationship between survival and gene mRNA expression levels. 
 
 
Figure 3. Evaluation of recurrence in patients with gene expression levels below and above the cutoff 
point. (A and B) Patients with MLH1, MSH2 mRNA expression levels above the cutoff point had longer 
the PFS compared to other patients. (C and D), Patients with ERCC1 and CTR1 mRNA expression levels 
above the cutoff point had shorter the PFS compared to other patients. 
 
Figure 3. Evaluation of recurrence in patients with gene expression levels below and above the cutoff point. (A and B) Patients with 
MLH1, MSH2 mRNA expression levels above the cutoff point had longer the PFS compared to other patients. (C and D), Patients with 
ERCC1 and CTR1 mRNA expression levels above the cutoff point had shorter the PFS compared to other patients.
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to patients with high levels (HR: 2.64, 95% CI 
= 0.27-25.56). Additionally, the PFS of patients 
with MSH2 mRNA expression level below the 
cutoff point was better compared to patients 
with expression levels above the cutoff point 
(HR:0.27, 95% CI = 0.03-2.47) (Table 4). On 
the contrary, the median survival of patients 
with expression levels of ERCC1 and CTR1 
mRNA above the cutoff point was 6 months 
(95% CI = 3.85-8.14) and 6 months (95% CI = 
0.2-33.79), respectively. Interestingly, poorer 
PFS was noted in patients with expression 
levels of ERCC1 and CTR1 above the cutoff 
point (HR: 4.6, 95% CI = 0.47-44.33 and 
HR: 3.08, 95% CI = 0.34-27.75, respectively) 
compared to patients whose expression levels 
were below the cutoff point (Table 4). 
The PFS rates were assessed for expression 
levels of MLH1, ERCC1, MSH2, and CTR1 
mRNA schemed by Kaplan-Meier survival 
curves (Figure 3). The results showed any 
significant difference between R and NR 
groups. It seems that increasing the sample 
size will produce significant differences in the 
results of other studies.
Discussion
One of the main challenges of clinicians is 
drug resistance and response to chemotherapy 
agents. The optimal effect of chemotherapy 
agents on tumor cells can be achieved by 
clarifying their molecular biology, which 
results in reduced resistance and increased 
patient survival. Considering the complexity 
of chemotherapy response, predicting the 
outcome of chemotherapy agents can be 
beneficial for treatment decision-making. 
Therefore, a unique therapeutic regime is 
necessary to overcome drug resistance. 
Identification of mechanisms of response to 
anticancer drugs and the genetic profile of 
the patients would make it possible to use 
personalized drugs based on molecular patterns. 
Anticipation of response to chemotherapy 
can be helpful for clinical decision-making 
to find optimal treatment strategies. Cisplatin 
resistance is widely common in patients treated 
with cisplatin-based chemotherapy (29). 
Several molecular mechanisms are involved in 
cisplatin resistance in different cancers. Among 
these mechanisms, NER and MMR pathways 
not only have a critical role in genetic stability, 
but are also involved in drug resistance and 
response to chemotherapy (18, 30-32).
No molecular biomarkers have yet been 
identified to overcome drug resistance in 
Iranian BC patients. Therefore, ERCC1, 
MLH1, MSH2, and CTR1 genes were selected 
in order to suggest a genetic panel for Iranian 
BC patients as a promising approach for 
clinical trials or cohort studies in the future. 
Studies have demonstrated that low 
expression of ERCC1 within the tumors 
improves the response to chemotherapy based 
on cisplatin and the outcome of cancer by 
decreasing the removal of cisplatin- induced 
DNA adducts resulting in increased survival 
(21, 33-35). Mullane et al. reported that 
DNA repair pathway largely contributed to 
prognosis of MIBC patients. The results of the 
expression level by immunohistochemistry 
showed that high expression levels of ERCC1 
played a key role in survival of patients 
who received cisplatin as the first line of 
chemotherapy (35). The results demonstrated 
that ERCC1 mRNA expression levels above 
the cutoff point might lead to decreased 
survival in patients. Moreover, the expression 
level of ERCC1 was higher in the R group 
compared to the NR group although the 
difference was not statistically significant, 
which can be explained by the small sample 
size of the study. 
Defects in genetic integrity may lead to 
disorders in the MMR system, especially 
MSH2 and MLH1. Consequently, defects in 
these factors alter the propensity of invasive 
tumor cells for metastasis and change their 
sensitivity to chemotherapeutic drugs (18, 22). 
Several studies revealed that lack of MLH1 
and MSH2 could induce cisplatin resistance 
in tumor cells, whereas low expression levels 
of MLH1 and MSH2 resulted in poor survival 
in ovarian and bladder cancer patients treated 
whit platinum drugs (36-38). In a study by 
Goodspeed et al., MSH2 knockdown in 
bladder cancer cell lines resulted in apoptosis- 
induced cisplatin reduction. Furthermore, the 
results demonstrated decreased survival in 
MIBC with a low expression level of MSH2 
protein after treatment with platinum- based 
chemotherapy (37). 
We investigated whether MLH1 and 
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MSH2 mRNA expression levels below the 
cutoff point had any effects on the poor 
survival of these patients but the results were 
not significant because of the small sample 
size. Generally, this pattern was observed in 
both groups of patients, which can be used 
for designing RCT and cohort studies in the 
future. Moreover, it should be noted that the 
expression of these genes was reduced in the 
R group compared to the NR group. However, 
the results may vary according to the cancer 
type, for instance, some studies showed 
that low levels of MSH2 expression were 
associated with a high survival in non- small 
cell lung cancer and were not associated with a 
poor survival in ovarian cancer (39, 40). 
Other mechanisms that attribute to cisplatin 
resistance include decreased accumulation of 
cisplatin due to low expression of transporters. 
Among them, studies have shown that 
CTR1 regulates the copper intracellular 
concentration, which plays a crucial role in 
the uptake or influx of cisplatin. Therefore, 
low levels of CTR1 mRNA expression reduce 
cisplatin sensitivity (25, 41 and 42). Kilari et 
al. investigated the correlation between CTR1 
expression and pathological outcome in pre- 
and post- chemotherapy tissues and suggested 
that CTR1 immuno-expression could be used 
as a biomarker before NAC (neoadjuvant 
chemotherapy)- TURBT in order to predict 
the risk of NAC for individual patients (25). 
To the best of our knowledge, the correlation 
between CTR1 and survival of BC patient is 
not clear. In our study, the CTR1 expression 
level was higher in the R group compared 
to the NR group, which was associated with 
increased survival. In addition, our results 
failed to obtain statistical significance that can 
be explained by the small sample size. 
One of the limitations that can be 
highlighted is the exclusion of patients who 
underwent other treatment strategies. Other 
limitations were difficulty in obtaining fresh 
tumor tissues during the surgery and follow-
up patients after chemotherapy. Another 
limitation was conducting the study in two 
centers while more centers were needed, 
which was not allowed. In addition, this report 
is related to a small sample of Iranian patients 
and is indeed a primary study for selecting the 
genes that can be used as markers in future 
investigations. Moreover, longer follow-up 
times are required to prevent bias. We could 
not unravel the relationship between the 
expression level of these genes as molecular 
markers and response to chemotherapy. 
However, in these patients, response to 
chemotherapy during the follow-up period 
was consistent with our hypothesis. 
Conclusion
In conclusion, the expression levels of 
ERCC1, MLH1, MSH2, and CTR1 were 
assessed in BC patients. The PFS and risk 
of disease recurrence were successfully 
measured. Despite a non-significant difference 
in gene expression between R and NR groups, 
a correlation was observed between gene 
expression level and risk of disease recurrence 
that was consistent with other studies. 
Therefore, these genes can be suggested as a 
model of gene profiling for personalized cancer 
treatment to not only reduce treatment costs 
but also to increase the survival of the patients. 
The suggested model of gene profiling can be 
a promising strategy for cohort and clinical 
studies with larger sample sizes in different 
populations. 
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